Another Trial Supports Low-Dose Abiraterone Acetate in mCRPC

/in , , /by

This study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]

Read more

Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)

/in , , /by
Read more

Update: HLD-0915 Advances with FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer

/in , , , /by
Read more

Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond

/in , , , /by
Read more